For patients with intermediate-high-risk acute pulmonary embolism, catheter-directed thrombolysis with alteplase plus ...
Key takeawaysPulmonary embolism (a blood clot in the lungs) is the third most common cause of cardiovascular death, but there ...
In patients with intermediate-high-risk pulmonary embolism, catheter-directed thrombolysis improved short-term clinical ...
In patients with intermediate-high-risk pulmonary embolism, catheter-directed thrombolysis improved short-term clinical ...
In patients with intermediate−high risk pulmonary embolism, catheter-directed thrombolysis improved short-term clinical ...
USA: The first dedicated pulmonary embolism (PE) guideline from the American Heart Association (AHA) and American College of Cardiology (ACC) provides clinicians with an updated framework ...
LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating ...
LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating ...
During a live event, Casey L. O'Connell, MD, and participants considered how white blood cell count may factor into risk ...
Many online questioned how long the blogger’s broadcast remained up on the app and shared mental health resources ...
Daiichi Sankyo and AstraZeneca ’s Enhertu is the first and only HER2 directed medicine to improve progression-free survival over global standard of care in a phase 3 trial in this setting Data to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results